GI
CGEM icon

GAMMA Investing’s Cullinan Oncology CGEM Stock Holding History

GAMMA Investing’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40.9K Buy
2,666
+738
+38% +$14.1K ﹤0.01% 2506
2026
Q2 		$35.1K Buy
1,928
+169
+10% +$2.51K ﹤0.01% 2538
2026
Q1 		$25K Buy
1,759
+779
+79% +$10K ﹤0.01% 2609
2025
Q4 		$10.1K Buy
980
+232
+31% +$2.09K ﹤0.01% 2969
2025
Q3 		$4.44K Buy
748
+159
+27% +$1.16K ﹤0.01% 3221
2025
Q2 		$4.43K Sell
589
-335
-36% -$2.69K ﹤0.01% 3171
2025
Q1 		$7K Buy
924
+392
+74% +$3.76K ﹤0.01% 2924
2024
Q4 		$6.48K Sell
532
-50
-9% -$719 ﹤0.01% 2804
2024
Q3 		$9.74K Buy
582
+78
+15% +$1.38K ﹤0.01% 2472
2024
Q2 		$8.79K Buy
504
+8
+2% +$170 ﹤0.01% 2313
2024
Q1 		$8.45K Buy
496
+84
+20% +$1.3K ﹤0.01% 2148
2023
Q4 		$6.24K Buy
+412
New +$3.65K ﹤0.01% 2135

Other funds holding CGEM

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.31B AUM 12.25% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's CGEM Position: Q3 2026 in Review

GAMMA Investing increased its Cullinan Oncology (CGEM) stake by 38% in Q3 2026, buying an estimated $14.1K and bringing the position to 2,666 shares worth $40.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2506.

GAMMA Investing first reported a position in CGEM in Q4 2023 and has held it in 12 quarters since. 4 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • GAMMA Investing held 2,666 shares of Cullinan Oncology worth $40.9K as of Q3 2026.
  • GAMMA Investing bought 738 Cullinan Oncology shares in Q3 2026, an estimated $14.1K.
  • Cullinan Oncology made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2506 holding.
  • GAMMA Investing first reported a position in Cullinan Oncology in Q4 2023 and has held it in 12 quarters since.
  • 4 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.